Intellia Therapeutics (NASDAQ:NTLA) CEO John Leonard Sells 9,000 Shares of Company Stock

Intellia Therapeutics, Inc. (NASDAQ:NTLA) CEO John Leonard sold 9,000 shares of the company’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $11.99, for a total transaction of $107,910.00. Following the completion of the sale, the chief executive officer directly owned 1,138,064 shares in the company, valued at $13,645,387.36. This trade represents a 0.78% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Intellia Therapeutics Stock Up 1.7%

Shares of Intellia Therapeutics stock traded up $0.20 during trading on Tuesday, hitting $11.86. 2,874,316 shares of the company were exchanged, compared to its average volume of 5,128,988. Intellia Therapeutics, Inc. has a fifty-two week low of $7.95 and a fifty-two week high of $18.48. The firm has a 50 day moving average price of $12.21 and a 200 day moving average price of $13.06. The stock has a market capitalization of $1.66 billion, a price-to-earnings ratio of -3.53 and a beta of 1.80.

Intellia Therapeutics (NASDAQ:NTLA) last announced its earnings results on Thursday, August 6th. The company reported ($0.80) EPS for the quarter, meeting analysts’ consensus estimates of ($0.80). The firm had revenue of $7.66 million for the quarter, compared to analysts’ expectations of $12.98 million. Intellia Therapeutics had a negative return on equity of 57.79% and a negative net margin of 672.16%. Intellia Therapeutics’s quarterly revenue was down 46.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.98) EPS. Analysts predict that Intellia Therapeutics, Inc. will post -3.21 earnings per share for the current year.

Hedge Funds Weigh In On Intellia Therapeutics

A number of large investors have recently modified their holdings of NTLA. Farther Finance Advisors LLC grew its holdings in shares of Intellia Therapeutics by 289.8% during the 3rd quarter. Farther Finance Advisors LLC now owns 2,144 shares of the company’s stock worth $26,000 after purchasing an additional 1,594 shares during the period. Parallel Advisors LLC raised its holdings in Intellia Therapeutics by 267.0% in the third quarter. Parallel Advisors LLC now owns 2,268 shares of the company’s stock valued at $27,000 after buying an additional 1,650 shares during the period. Freestone Grove Partners LP purchased a new position in Intellia Therapeutics in the second quarter valued at approximately $33,000. Nykredit A S purchased a new position in Intellia Therapeutics in the second quarter valued at approximately $33,000. Finally, Integrated Wealth Concepts LLC acquired a new position in Intellia Therapeutics during the second quarter valued at approximately $34,000. 88.77% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

NTLA has been the topic of several analyst reports. Citizens Jmp reaffirmed a “market outperform” rating and set a $30.00 price target on shares of Intellia Therapeutics in a research note on Wednesday, September 9th. Wolfe Research lowered Intellia Therapeutics from a “peer perform” rating to an “underperform” rating and set a $9.00 price target on the stock. in a research note on Wednesday, July 15th. Wedbush lifted their price objective on Intellia Therapeutics from $12.00 to $13.00 and gave the company a “neutral” rating in a research report on Wednesday, September 9th. HC Wainwright reiterated a “buy” rating and issued a $25.00 target price on shares of Intellia Therapeutics in a research note on Wednesday, September 9th. Finally, Evercore upgraded Intellia Therapeutics from a “hold” rating to an “outperform” rating and set a $24.00 target price on the stock in a research report on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, seven have issued a Hold rating and five have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $20.57.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc is a biotechnology company focused on developing potentially curative treatments using CRISPR-based gene-editing technology. The company is working to create therapies that can modify disease-causing genes inside the body, with the goal of addressing the underlying causes of serious genetic diseases rather than treating only their symptoms.

Intellia’s pipeline has included NTLA-2001, an investigational in vivo gene-editing therapy designed to reduce production of transthyretin for the treatment of transthyretin amyloidosis, and NTLA-2002, an investigational therapy intended to target hereditary angioedema.